natgillin/translations-raw huggingface dataset:
A method of determining a prognosis for a patient at risk for developing Alzheimer's disease is provided, including obtaining a patient profile, wherein the obtaining a patient profile includes: detecting the presence or absence of at least one ApoE allele in a biological sample of the patient, and detecting the presence or absence of at least one TOMM40 deletion/insertion polymorphism (DIP) located in intron 6 or intron 9 of the TOMM40 gene, and then, converting the patient profile into the prognosis, wherein the presence of the ApoE allele and the presence of the at least one TOMM40 DIP polymorphism identifies the patient as a patient at risk for developing Alzheimer's disease. 
Postupak određivanja prognoze ili rizika za razvoj Alzheimerove bolesti kod pacijenta, naznačen time, da obuhvaća dobivanje pacijentovog profila, pri čemu dobivanje pacijentovog profila sadrži sljedeće korake: otkrivanje prisutnosti ili odsutnosti najmanje jedne alele ApoE 2, ApoE 3 ili ApoE 4, u biološkom uzorku od spomenutog pacijenta; i otkrivanje prisutnosti ili odsutnosti najmanje jednog polimorfizma s TOMM40 izbacivanjem/umetanjem (DIP), smještenog u intronu 6 ili intronu 9 od TOMMA40-gena; te tada pretvaranje spomenutog profila pacijenta u navedene prognoze, pri čemu prisutnost spomenute alele ApoE 2,
The vesicles of claims 1-5, wherein the EGF is incorporated into the vesicle bilayer. 
Čestice iz bilo kojeg od patentnih zahtjeva 1-4, pri čemu se EGF inkorporira u dvostruki sloj vezikule.
In order to accept requests for the current network-related user data, a specific register node or all of the register nodes in the network can be designed to receive a request of a system for the user data of a specific terminal, and to carry out a search for this user data within the network, using the method steps described above. 
Telekomunikacijska mreža (T) temeljem jednog od zahtjeva 7 do 11, naznačena time što određeno rTegistracijsko čvorište ili sva registracijska čvorišta (CDNR3, DNLR2) je ili su konfigurirana da primaju zahtjev sustava za korisničke podatke povezane s mrežom određenog terminala (UE), i da izvršava pretragu za tim korisničkim podacima unutar mreže (N).
The tablet of claim 1, wherein the disintegrating or eroding tablet matrix of the second layer comprises one or more fillers, a disintegrant, a lubricant and, optionally, a binder, a flow control agent or other excipients and adjuvants. 
Tableta prema zahijevu 1, naznačena time, da tabletna matrica drugog sloja, koja se rastavlja primjerice dezintegrira ili erodira, sadrži jedno ili više punila, sredstvo za dezintegraciju, lubrikant te opcijski vezivo, protočno kontrolno sredstvo ili ostale pomoćne tvari i dopunska sredstva.
The formulation of claim 9, wherein the concentration of NaOAc/HOAc is from about 10 to 30 mM and the concentration of NaH2PO4 is from about 25 to 75 mM. 
Formulacija prema zahtjevu 9, naznačena time da je koncentracija NaOAc/HOAc od oko 10 do 30 mM i koncentracija NaH2PO4 je od oko 25 do 75 mM.
The pharmaceutical composition for use according to claim 5, wherein the composition further comprises an excipient selected from mannitol, microcrystalline cellulose, crospovidone, and magnesium stearate, or wherein the composition further comprises a permeation enhancer. 
Farmaceutski sastav za upotrebu prema bilo kojem od zahtjeva 1 do 8, gdje sastav dalje sadrži pomoćnu tvar izabranu između manitola, mikrokristalne celuloze, krospovidona i magnezijeva stearata.
The process according to claim 3, wherein compounds of Formula XX are selected from: 
Postupak u skladu s patentnim zahtjevom 3, naznačen time, da su spojevi Formule XX odabrani među sljedećim spojevima:
In another embodiment, the salt of formula VII is first converted to a corresponding alkaline metal salt, particularly the sodium salt, which is subsequently converted to the pharmaceutically acceptable salt. 
Postupak prema zahtjevu 12, naznačen time, da se sol formule VII prvo pretvara u odgovarajuću sol alkalijskog metala, posebno u natrijevu sol, koja se uzastopno pretvara u farmaceutski prihvatljivu sol rosuvastatina.
separating the pulverulent part and metallic crusts of the residue material by means of rotation of said residue material within said confined environment consisting of the rotating drum. 
gašenje i razgradnju rezidualnog materijala unutar ograničenog okoliša koji se sastoji od rotirajućeg bubnja (6) s hlađenjem induciranog materijala putem zračne struje;
The high protein, fruit-flavoured beverage according to any one of the preceding embodiments, wherein the fruit flavouring agent is selected from orange flavour, lemon flavour, lime flavour, pine apple flavour, apple flavour, pear flavour, strawberry flavour, cherry flavour, cranberry flavour, grape fruit flavour. 
Visokoproteinski napitak s voćnom aromom u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što sredstvo za davanje voćne arome se bira između arome naranče, arome limuna, arome limete, arome ananasa, arome jabuke, arome kruške, arome jagode, arome trešnje, arome brusnice, arome grejpa.
A method of treating psychotic, neurological and cognitive functions diseases and disorders in a mammal, comprising administration to a subject in need therefor of a therapeutically effective amount of the compound as defined in claim 1 . 
Spoj kako je definiran u bilo kojem zahtjevu 1 do 11, naznačen time da se koristi u metodi liječenja psihotičkih, neuroloških bolesti ili poremećaja 1 bolesti ili poremećaja kognitivnih funkcionalnosti kod sisavaca, pri čemu navedena metoda podrazumijeva administraciju osobama u potrebi terapeutski učinkovite količine spoja kako je definiran u bilo kojem od zahtjeva 1 do 11.
An antibody-like binding protein comprising two polypeptide chains that form two antigen binding sites capable of specifically binding one or more antigen targets, wherein a first polypeptide chain has a structure represented by the formula: 
Protutijelu sličan vezivni protein koji sadrži dva polipeptidna lanca koji tvore dva mjesta vezivanja antigena, pri čemu prvi polipeptidni lanac ima strukturu predstavljenu s formulom: VLi-Li-VLeLo-CL_
is selected from the group consisting of Br and Cl; 
R> je odabran iz skupine koju čine Br i Cl;
A pharmaceutical composition according to any one of claims 1 to 14 for use in a method for the treatment of a 5-HT2A serotonin receptor-related disorder. 
Farmaceutski pripravak prema bilo kojem od zahtjeva 1 do 14 za uporabu u postupku za liječenje poremećaja povezanog sa serotoninskim receptorom 5-HT22.
Preferably, according to the invention, two distinct cutting portions of the edge of the body 2 are present, one intended for cutting the scion and the other the rootstock. 
Alat u skladu s patentnim zahtjevom 1, naznačen time, da navedeni rub tijela (2) ima dva odvojena dijela za rezanje namijenjena rezanju mladice odnosno podloge koje se spajaju kako bi se dobila presađena biljka.
The medicament of claim 9 for the prophylaxis or treatment of circulatory diseases. 
Lijek u skladu sa zahtjevom 9, naznačen time, da se koristi za profilaksu ili liječenje cirkulacijskih oboljenja.
Method to obtain and to produce massively a monoculture of a cyanobacterial species according to claim 6, wherein the culture medium has a final allantoic acid concentration of 1.0 mM. 
Postupak prema zahtjevu 1, gdje medij kulture ima konačnu koncentraciju alantoinske kiseline 1.0 mM.
Blockade of dopamine may also worsen negative symptoms and cognitive functioning by further decreasing the amount of dopamine in the frontal cortex. 
Blokada dopamina može također pogoršati negativne simptome i kognitivno funkcioniranje daljnjim smanjivanjem količine dopamina u frontalnom korteksu.
Use in vitro of an indicating agent in evaluating mental conditions selected from the group consisting of mental fatigue, physical fatigue, stress, anxiety, depression and schizophrenia, which indicating agent comprises at least eight kinds of cytokines selected from the group consisting of IL-1B, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, Eotaxin, FGF basic, G-CSF, GM-CSF, IFN-Y, IFN-a, IP-10, MCP-1, MIP-1a, MIP-1B, PDGF-BB, RANTES, TNF-a, VEGF, CSF-2, TGF-B, neurotrophin 5, MCP-3, B-2-microglobulin, angiotensin II, CSF-3, CXC chemokine ligand 1, CXC chemokine ligand 5 and HGF, wherein the amount of each cytokine is multiplied by a weighting coefficient. 
Uporaba in vitro indikacijskog sredstva za vrednovanje mentalnih stanja, naznačena time, da su ta stanja odabrana iz skupine koju čine: mentalna iscrpljenost, fizička iscrpljenost, stres, anksioznost, depresija i shizofrenija, pri čemu indikacijsko sredstvo sadrži najmanje osam vrsta citokina odabranih iz skupine koju čine: IL-1B, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-15, IL-17, eotaksin, osnovni FGF, G-CSF, GM-CSF, IFN-Y, IFN-a, IP-10, MCP-1, MIP-1a, MIP-1B, PDGF-BB, RANTES, TNF-a, VEGF, CSF-2, TGF-B, neurotrofin 5, MCP-3, B-2-mikroglobulin, angiotenzin II, CSF-3, CXC ligand kemokina l, CXC ligand kemokina 5 i HGF, gdje je količina svakog citokina pomnožena s koeficijentom faktora težine.
The kit of claim 9, wherein the therapeutic component is selected from the group consisting of a reservoir for active agent, a metallic wire, and a combination thereof. 
Set prema zahtjevu 9, naznačen time što se terapijska komponenta (1b) izabire iz grupe koja obuhvaća spremnik djelatne tvari, metalnu žicu i njihovu kombinaciju.
It was subsequently filtered to dryness. 
Nakon toga je profiltriran do suhoće.
A hand held medicine dosing and dispensing device according to Claim 14 or Claim 15 wherein the ejection mechanism further includes at least one biasing member to eject the cassette from the housing on disengagement of the latch members. 
Ručni uređaj za doziranje 1 izdavanje lijeka prema zahtjevu 14 ili zahtjevu 15 naznačen time da mehanizam za izbacivanje nadalje sadrži barem jedan element za potiskivanje za izbacivanje kasete iz kućišta kod oslobađanja elemenata zasuna.
no more than 5% of each of methionine 112 and methionine 148 in said ApoA-I in said population is oxidized; no more than 4% of the amino acids of the ApoA-I in said population is deamidated; 
oksidirano je ne više od 20%, ne više od 15%, ne više od 10%, ne više od 5%, ne više od 3%, ne više od 2% ili ne više od 1% od svakog metionina 112 i metionina 148 u navedenom ApoA-I u navedenoj populaciji;
The humanized antibody or antigen binding fragment thereof or composition or pharmaceutical composition for the use according to claim 13, wherein the cancer is selected from the group consisting of ovarian cancer, skin cancer, renal cancer, colorectal cancer, sarcoma, leukemia, brain cancer, thyroid cancer, breast cancer, prostate cancer, oesophageal cancer, bladder cancer, lung cancer and head and neck cancer and/or wherein the cancer is metastatic. 
Humanizirano protutijelo ili njegov fragment koji veže antigen ili pripravak ili farmaceutski pripravak za uporabu prema zahtjevu 13, naznačen time, da je rak odabran iz skupine koja se sastoji od sljedećih: rak jajnika, rak kože, rak bubrega, kolorektalni rak, sarkom, leukemija, rak mozga, rak tiroidne žlijezde, rak dojke, rak prostate, rak jednjaka, rak mjehura, rak pluća 1 rak glave 1 vrata i/ili time, da je rak metastatski.
The compound or a salt thereof according to claim 6, wherein R12 is halogen or halogeno-C1-6 alkyl, and R11, R13 and R14 are H. 
Spoj ili njegova sol u skladu sa patentnim zahtjevom 6, gdje R12 je halogen ili halogeno-C1-6 alkil, i R11, R13 i R14 su H.
A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers for use in a method of treating cancer. 
Farmaceutski sastav, naznačen time, da obuhvaća terapeutski djelotvornu količinu spoja prema bilo kojem od zahtjeva 1 do 5 ijedan ili više farmaceutski prihvatljivih nosača.
In those preservatives, boron, quaternary ammonium compound or azoles are used as cobiocides, and ethanolamine as fixative. 
U tim konzervansima, upotrebljavaju se bor, kvaterni spoj amonija ili azoli kao ko-biocidi, i etanolamin kao fiksator.
for use in the subsequent hydrogenation step. 
za uporabu u kasnijoj fazi hidrogenizacije.
and R8 are independently hydrogen, alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, heteroalkyl, heteroalkenyl, or 
i R8 su nezavisno vodik, alkil, supstituirani alkil, cikloalkil, supstituirani cikloalkil, aril, supstituirani aril, heteroaril, supstituirani heteroaril, heterocikloalkil, heteroalkil, heteroalkenil, ili
the cellulosic biomass the cellulosic biomass comprises wood or wood residues; and ii) the unenriched renewable fuel oil has a solids content of less than 0.5 wt. 
Postupak prema jednom od zahtjeva 1 do 3, naznačen time što neobogaćeno obnovljivo ulje goriva ima sadržaj krutina od manje od 0,5 wt.
JP 61-037752 uses a chromatographic process on a co-polymer, containing monovinyl and polyvinyl aromatic monomers. 
JP 61-037752 upotrebljava kromatografski postupak na kopolimeru, koji sadržava monovinil i polivinil aromatske monomere.
An anti-parasitic pour-on composition characterised by the presence of a delivery system comprising (i) at least 20% (v/v) of one or more alcohols, (ii) an effective amount of a salicylanilide anti-parasitic compound, and, optionally, (iii) polyethylene glycol as a polymeric entity. 
Antiparazitna smjesa za polijevanje koja sadrži učinkovitu količinu salicilanilidnog anti-parazitnog spoja, naznačena prisutnošću transdermalnog sustava primjene koji sadrži barem 20% (v/v) jednog ili više od C1-C6 monohidro alkilnih alkohola.
receiving an indication the mass of unreacted core within the rotating cylindrical body; 
prijem indikacije iz nadzornog sustava elektrane o masi ne-reagirane jezgre (11) unutar rotirajućeg cilindričnog tijela (110);
a data element corresponding to the measured consumption of utilities is stored in a respective subsequent one of said storage locations of said circular storage means (CSM), and 
- element podataka koji odgovara izmjerenoj potrošnji komunalnih usluga se pohranjuje u dotičnoj sljedećoj navedenoj lokaciji za pohranu u cirkularnom sredstvu pohrane (CSM), i
wherein the flexible bag has a second chamber and the first chamber and the second chamber are separated by a breakable seal, wherein the pharmaceutical product is a cytotoxic drug, and 
drugu komoru (120) odvojenu od prve komore (110), pri čemu je druga komora (120) konfigurirana da sadržava otopinu za rekonstituiranje, za rekonstituiranje liofiliziranog farmaceutskog proizvoda u prvoj komori (110);
An antibody or antigen-binding fragment thereof according to claim 4 wherein the heavy chain and/or the light chain comprise in their frameworks all the following amino acid residues: 
Antitijelo ili njegov antigen-vezujući fragment u skladu s patentnim zahtjevom 4, naznačeno time što težak lanac ifili lak lanac sadrže u svojim okvirima sve sljedeće aminokiselinske ostatke:
The method of Claim 9, wherein Y is an optionally substituted phenyl, an optionally substituted pyridyl, an optionally substituted thiophenyl, [1,2,3]thiadiazolyl, an optionally substituted isoxazolyl, 1 H -pyrazolyl, quinolinyl, imidazolyl, or 2,3-dihydrobenzo[1,4]dioxine. 
Farmaceutski pripravak prema zahtjevu 45, naznačen time da Y1 je opcijski supstituiran fenil, opcijski supstituiran piridil, opcijski supstituiran tiofenil, [1,2,3]tiadiazolil, opcijski supstituiran izoksazolil, 1H-pirazolil, kvinolinil, imidazolil, ili 2,3-dihidrobenzo[1,4]dioksin.
An apparatus according to claim 12, wherein the unloading channel is sloped downward from the first end to the second end thereof. 
Aparat prema patentnom zahtjevu 10, gdje kanal (122) za istovar je nagnut prema dolje od prvog kraja do drugog kraja istog.
n is selected the group consisting of 0, 1, and 2; B is cyclic structure selected from the group consisting of cycloalkyl; cycloalkenyl; 
nje odabran od 0; 1 ili 2; B predstavlja cikličku strukturu odabranu od cikloalkila; cikloalkenila; cikloalkinila; arila; i heterocikla;
GC-MS analysis of the hexanic residue of example 4 
Broj objave europskog patenta:
In another embodiment, thermal stability, refolding, expression yield, aggregation and/or binding activity of the immunobinder is not adversely affected by the mutating. 
Postupak prema bilo kojem od zahtjeva 3 do 7, naznačen time, da _nema štetnog utjecaja na toplinsku stabilnost, ponovno savijanje, doprinos ekspresije, agregaciju i/ili na aktivitet vezanja za imunovezno sredstvo prilikom mutacije.
the upper limit of trypsin activity in said composition is less than 4, 3, 2, or 1.56 ng per 1 mg of mature type I elastase protein, optionally wherein the upper limit of trypsin activity in said composition is quantified using a an N-benzoyl-Phe-Val-Arg pNitroanilide (BENZ) colorimetric trypsin activity assay; 
(a) gornja granica aktivnosti tripsina u spomenutom sastavu je manja od 4, 3, 2 ili 1,56 ng po 1 mg zrelog tipa I protein elastaze, pri čemu je opcionalno gornja granica aktivnosti tripsina u spomenutom sastavu kvantificirana koristeći N-benzoil-Phe-Val-Arg pNitroanilid (BENZ) kolorimetrijski test aktivnosti tripsina;
The composition according to claim 1, wherein the at least one oxidant is selected from the group consisting of hydrogen peroxide at 3.5% to 6% of the total composition, carbamide peroxide at 10% to 16% of the total composition, and benzoyl peroxide at 2.5% to 5% of the total composition The composition according to claim 1, further comprising at least one healing factor selected from hyaluronic acid, glucosamine and allantoin. The composition according to any one of claims 1-4, which further comprises at least one hydrophilic gelling agent selected from glucose, modified starch, methyl cellulose, carboxymethyl cellulose, propyl cellulose, hydroxypropyl cellulose, carbopol(RTM) polymers, alginic acid, sodium alginate, potassium alginate, ammonium alginate, calcium alginate, agar, carrageenan, locust bean gum, pectin, and gelatin. 
Kompozicija za primjenu prema patentnom zahtjevu 1, gdje peroksid je odabran iz grupe koja se sastoji od vodik peroksida pri 3.5% do 6% ukupne kompozicije, karbamid peroksida pri 10% do 16% ukupne kompozicije, i benzoil peroksida pri 2.5% do 5% ukupne kompozicije Kompozicija za primjenu prema patentnom zahtjevu 1 ili 2, koja dalje sadrži najmanje jedan hidrofilni agens za geliranje odabran od glukoze, modificiranog škroba, metil celuloze, karboksimetil celuloze, propil celuloze, hidroksipropil celuloze, karbopol (RTM) polimera, alginske kiseline, natrij alginata, kalij alginata, amonij alginata, kalcij alginata, agara, karagenana, karuba gume, pektina, i želatina.
Further Embodiments A solid composition for oral administration comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, wherein the amount of said salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid is at least 0.6 mmol. 
Čvrsta kompozicija za oralnu primjenu koja sadrži agonist GLP-1 i sol N-(8-(2-hidroksibenzoiljamino)kaprilne kiseline, pri čemu je količina navedene soli N-(8-(2-hidroksibenzoil)amino)kaprilne kiseline najmanje 0.6 mmol; i pri čemu je navedeni agonist GLP-1 semaglutid.
a step of producing a compound of the formula (6) from a compound of the formula (8) produced by a Horner-Wadsworth-Emmons reaction and a compound of the formula (7); 
koraku dobivanja spoja formule (6) iz spoja formule (8), dobivenog Horner-Wadsworth-Emmonsovom reakcijom, i spoja formule (7);
A pharmaceutical composition, comprising: a therapeutically effective amount of the crystalline form of claim 1 or 2. 
Farmaceutski sastav, sadrži: terapijski učinkovitu količinu kristalnog oblika iz patentnog zahtjeva 1 ili 2.
In a third aspect the invention provides a method for the quantification of a vaccine strain and a virulent strain of Marek's Disease Virus Serotype-1 (MDV-1) in a sample from a bird, comprising the steps of: 
Postupak kvantificiranja cjepivnog soja i virulentnog soja virusa Marekove bolesti serotip-1 (MDYV-1) u uzorku iz ptice, naznačen time što se sastoji u koracima:
Preferably, the amorphous zirconia particles have a BET surface area of in the range of 250-550 m2/g, or 250-450 m2/g, such as in the range of 350-550 m2/g, or 350-550 m2/g. 
Preferirano čestice amorfnog cirkonijevog oksida imaju BET površine u rasponu od 250-550 m"/g, ili 250-450 m"/g kao stoje u rasponu od 350-550 m"/g, ili 350-550 m//g.
A process for treating a material having biomass or waste product, the process comprising: 
Postupak za obradu materijala, poput biomase ili otpada, koji se sastoji u:
The optical rotation was measured using a Bellingham Stanley ADP220 polarimeter and gave an [aD] of+123.5°. 
Optičko zakretanje je mjereno uporabom Bellingham Stanley ADP220 polarimetra i dobivena je vrijednost [ap] +123.5 ".
a compound of formula I wherein R1 is difluoromethyl or trifluoromethyl and X is chloro, fluoro or bromo; and the compound fenpropidin. 
(A) spoja formule (I) naznačen time da R, je difluorometil ili trifluorometil i X je kloro, fluoro ili bromo; i (B) barem jednog spoja odabranog iz skupine koja se sastoji od (Bl) - strobilurin fungicida.
A decoding device including first decoding means operating under a linear predictive coding scheme and second decoding means operating under a coding scheme which is different from the linear predictive coding scheme and decoding an encoded audio signal generated from an audio signal, using the first decoding means and the second decoding means, the decoding device comprising: 
Uređaj za dekodiranje (20), koji sadrži prvi dekoder (24), koji radi prema linearnoj prediktivnoj shemi kodiranja, i drugi dekoder (25), koji radi prema shemi kodiranja koja se razlikuje od linearne prediktivne sheme kodiranja, gdje se kodirani audio signal i dekodira uz pomoć prvog dekodera i drugog dekodera, naznačen time što uređaj za dekodiranje (20) sadrži:
an increase from baseline of evening peak expiratory flow rate (PM PEF) in liters/minute; 
(c) povećanje početne vrijednosti večernjeg vršnog ekspiratornog protoka (PM PEF) od najmanje 1.0 L/min;
The compound of any one of clauses (1)-(3) wherein at least one of E1a and E1b is cyclopropylcarbonylamino, cyclobutylcarbonylamino, cyclopropyloxycarbonylamino or cyclobutyloxycarbonylamino; 
Spoj iz bilo kojeg od patentnih zahtjeva 1-3 gdje najmanje jedno od E'* i E" je ciklopropilkarbonilamino, ciklobutilkarbonilamino, ciklopropiloksikarbonilamino ili ciklobutiloksikarbonilamino.
Fibra-Cel® disks are usually treated electrostatically to facilitate suspension cells adhering to the disks and becoming trapped in the fiber system, where they remain throughout the cultivation process. 
Diskovi Fibra-Cel* uobičajeno su tretirani elektrostatski kako bi se ubrzalo priljepljivanje stanica za diskove te kako bi stanice bile ulovljene u sustavu vlakana, gdje i ostaju tijekom cijeloga uzgojnog procesa.
The method according to Claim 8, wherein (1) the herbicidal sulfonylurea compound or its salt and (2) the polyoxyalkylene alkyl ether phosphate or its salt are applied in a weight ratio of from 13:1 to 1:10,000, and (2) the polyoxyalkylene alkyl ether phosphate or its salt and (3) the salt are applied in a weight ratio of from 500:1 to 1:5. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time, da (1) spoj sulfonil urjea herbicida ili sol istog i (2) polioksialkilen alkil eter fosfat ili sol istog su primjenjeni u masenom omjeru od 13:1 do 1:10,000 te (2) polioksialkilen alkil eter fosfat ili sol istog 1 (3) sol su primjenjene u masenom omjeru od 500:1 do 1:5.
An antibody, or a derived compound or functional fragment of same, according to claim 6, characterized in that it comprises a light chain comprising the CDR-L1 of the sequence SEQ ID No. 1, the CDR-L2 of the sequence SEQ ID No. 2 and the CDR-L3 of the sequence SEQ ID No. 3. 
– laki lanac koji prema IMGT sadrži CDR-L1 sekvencije SEQ ID No. 1, CDR-L2 sekvencije SEQ ID No. 2 te CDR-L3 sekvencije SEQ ID No. 3, te – teški lanac lanac koji prema IMGT sadrži CDR-H1 sekvencije SEQ ID No. 7, CDR-H2 sekvencije SEQ ID No. 5 te CDR-H3 sekvencije SEQ ID No. 8,